HEAL Commercialization Readiness Pilot (CRP) Program: Embedded Entrepreneurs for Small Businesses in Pain Management (SB1 Clinical Trial Not Allowed)

HEAL Commercialization Readiness Pilot (CRP) Program: Embedded Entrepreneurs for Small Businesses in Pain Management (SB1 Clinical Trial Not Allowed) is sponsored by National Institutes of Health (NIH) HEAL Initiative. This funding opportunity supports the commercialization of SBIR/STTR-funded pain management technologies.

Expired PAR-23-069: HEAL Commercialization Readiness Pilot (CRP) Program: Embedded Entrepreneurs for Small Businesses in Pain Management (SB1 Clinical Trial Not Allowed) This notice has expired. For NIH, in limited situations, applications may be accepted on a case-by-case basis for a short period after expiration to accommodate NIH late or continuous submission policies . Contact the eRA Service Desk for any submission issues.

Check the NIH Guide for active opportunities and notices. Department of Health and Human Services Part 1.

Overview Information Participating Organization(s) National Institutes of Health ( NIH ) Components of Participating Organizations National Institute of Neurological Disorders and National Eye Institute ( NEI ) National Institute of Arthritis and Musculoskeletal and Skin Diseases ( NIAMS ) National Center for Complementary and Integrative Health ( NCCIH ) National Center for Advancing Translational Sciences ( NCATS ) Funding Opportunity Title HEAL Commercialization Readiness Pilot (CRP) Program: Embedded Entrepreneurs for Small Businesses in Pain Management (SB1 Clinical Trial Not Allowed) SB1 Commercialization Readiness Program March 31, 2025 - This funding opportunity was updated to align with agency priorities.

Carefully reread the full funding opportunity and make any needed adjustments to your application prior to submission. April 04, 2024 - Overview of Grant Application and Review Changes for Due Dates on or after January 25, 2025. See Notice NOT-OD-24-084 November 14, 2023 - Clarification of Implementation of the NIH SBIR and STTR Foreign Disclosure Pre-award and Post-Award Requirements.

See Notice NOT-OD-24-029 June 12, 2023 - Implementation of the NIH SBIR and STTR Foreign Disclosure Pre-award and Post-Award Requirements. See NOT-OD-23-139 . ( See updates incorporated into NOFO content in Sections IV, V, VI, and VIII applicable for applications submitted for due dates on or after September 5, 2023.

) February 23, 2023 - Notice of Change to Minimum Performance Standards for SBIR and STTR Applicants. See Notice NOT-OD-23-092 .

NOT-OD-22-195 - New NIH "FORMS-H" Grant Application Forms and Instructions Coming for Due Dates on or after January 25, 2023 NOT-OD-22-189 - Implementation Details for the NIH Data Management and Sharing Policy NOT-OD-22-198 - Implementation Changes for Genomic Data Sharing Plans Included with Applications Due on or after January 25, 2023 Funding Opportunity Announcement (FOA) Number Companion Funding Opportunity See Section III. 3.

Additional Information on Eligibility . Assistance Listing Number 93. 853, 93.

846, 93. 213, 93. 867, 93.

350 Funding Opportunity Purpose The purpose of this Funding Opportunity Announcement (FOA) is to facilitate the transition of previously funded SBIR and STTR Phase II and Phase IIB projects in pain management to the commercialization stage by providing additional assistance for private partnering activities through the Commercialization Readiness Pilot (CRP) program.

Specifically, this FOA supports the addition of entrepreneurial expertise into small business leadership teams along with supporting partnering activities to aid in commercialization through private third-party funding or partnership with industry. Clinical trials are not accepted under this FOA.

Open Date (Earliest Submission Date) Letter of Intent Due Date(s) 30 days prior to the application due date The following table includes NIH standard due dates marked with an asterisk. Renewal / Resubmission / Revision (as allowed) All applications are due by 5:00 PM local time of applicant organization.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Required Application Instructions It is critical that applicants follow the SBIR/STTR (B) Instructions in the SF424 (R&R) SBIR/STTR Application Guide , except where instructed to do otherwise (in this FOA or in a Notice from the NIH Guide for Grants and Contracts ).

Conformance to all requirements (both in the Application Guide and the FOA) is required and strictly enforced. Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in Section IV . When the program-specific instructions deviate from those in the Application Guide, follow the program-specific instructions.

Applications that do not comply with these instructions may be delayed or not accepted for review. Part 1. Overview Information Part 2.

Full Text of Announcement Section I. Funding Opportunity Description Section II. Award Information Section III.

Eligibility Information Section IV. Application and Submission Information Section V. Application Review Information Section VI.

Award Administration Information Section VII. Agency Contacts Section VIII. Other Information Part 2.

Full Text of Announcement This FOA is part of the NIH HEAL (Helping to End Addiction Long-term) Initiative an aggressive, trans-agency effort to speed scientific solutions to stem the national opioid public health crisis. More information about the HEAL Initiative is available at https://heal. nih.

gov . More than 25 million Americans suffer from chronic pain, a highly debilitating medical condition that is complex and lacks effective treatments. In recent decades, there has been an overreliance on opioids for chronic pain despite their poor ability to improve function.

This contributed to a significant and alarming epidemic of opioid overdose deaths and addictions. Small Business support through the HEAL Initiative is dedicated to bringing innovative pain management technologies and treatments for pain to the market.

Due to their long and expensive development timelines, many pain management technologies, including small molecule and biologic analgesics, medical technologies, and diagnostics, require significant funding beyond federal support to reach the marketplace. Within small biotech companies, third-party funding is primarily achieved through attracting private investment and/or partnerships with industry.

Successfully attracting private partners requires dedicated time, significant knowledge, and unique skillsets. Early-stage biotech companies formed by technical experts may lack experience in business development, fundraising, private partnership, and entrepreneurship.

In addition, Small Business Concerns (SBCs) primarily supported through SBIR/STTR awards often lack funding for non-R&D activities, thus these SBCs may not be able to support the salaries of business development staff.

Gaps in entrepreneurial and business development expertise within SBCs may negatively impact the likelihood of attracting private funding and ultimately delay or undermine commercialization of innovative pain management products.

This FOA will prioritize applicants who demonstrate a need for private partnership to achieve commercialization of their pain management technologies, and SBCs who have not previously garnered significant private funding.

Small businesses who have previously obtained private funding should provide a clear rationale as to why additional business management expertise and federal support of partnering goals are needed to support future private partnering.

In demonstrating a need for federal support for successful private partnering, applicants should also address the relative accessibility of private partners in the geographical vicinity of the applying SBC. The CRP Program is an authorized component of the SBIR and STTR programs.

The CRP program permits utilization of SBIR/STTR set-aside funds to support eligible SBCs in conducting technical assistance activities which may not include an R&D component.

In concordance with the CRP program, funding through this FOA is intended to facilitate the transition of previously funded SBIR/STTR Phase II and Phase IIb projects focused on pain management to the commercialization stage by supporting private partnering activities. Please note: Only those applicants who have received Phase II or Phase IIB funding from NIH are eligible for CRP funding, as described in Section III. 1.

Specifically, applying SBCs must have at least one of the following: Phase II or IIB SBIR/STTR award that has ended within the last 36 months or will close out by the requested start date ("Type 2" Renewal application). Phase II or IIB SBIR/STTR award that will be active at the requested Project Start date ("Type 1" New application).

This FOA is specifically designed to support addition of an expert in entrepreneurship and business development within small business leadership teams which currently lack this knowledge base, and to utilize this expertise in efforts to attract private funding.

This FOA is designed to support applications with the following components within the Research Plan section of the application package (see Section IV for application instructions): A detailed hiring plan to fill gaps in business expertise within the current small business leadership through hiring of a qualified individual Clear identification of the specific skillsets and expertise missing from the current leadership team (or are only available in a leadership member with less than a 50% commitment) that must be filled to improve likelihood of attaining private partnering goals.

Methods by which at least three candidates filling the identified gaps in expertise will be identified, interviewed, and evaluated, including how the search will encourage applications from qualified individuals.

Identification of the executive level position, roles and responsibilities, anticipated compensation (including contributions of the applying small business), and level of effort (50%-100%) of the individual to be hired through this funding opportunity to fill identified gaps in expertise Biosketches and letters of support from one or more candidates fitting the identified gaps in expertise, indicating the candidate supports the proposed leadership role, compensation, and partnering plan A detailed partnering plan to attract private funding through private investment and/or partnership with industry (such as licensing or acquisition) the includes the following components: A description of the types of private investors or industry partners that will be targeted and how they align with the company, pain management technology, and mission of the HEAL Initiative Methods for identifying and contacting potential private partners A timeline for execution of proposed activities extending throughout the proposed grant period Interim goals or milestones throughout the grant period This funding opportunity is intended to bolster the core competencies of NIH-funded SBC leadership teams in areas of business expertise and private partnering in an effort to improve success in private funding and partnering.

Therefore, applicants are expected to incorporate this expertise into the SBC leadership team at a significant commitment of no less than 50% effort to the company. Note that the level of effort of this individual on the proposed project may be less than the overall commitment to the company.

For example, the individual may be a full time hire and be proposed to contribute 50% effort to the activities proposed to this funding opportunity. Level of effort on the proposed project should be commensurate with the involvement of the individual in the proposed partnering activities. Award funding may only support the labor costs affiliated with the proposed activities.

Applying small businesses are expected to contribute to the compensation of individual(s) hired through this award.

The proposed hire is expected to be responsible for significant portions of business development and private partnering activities, and therefore it is anticipated that executive positions such as Chief Business Officer (CBO), Chief Finance Officer (CFO), Chief Executive Officer (CEO), Chief Operations Officer (COO), Senior VP of Business Development, or similar may be appropriate.

It is anticipated that relevant skillsets and expertise needed to conduct partnering activities may include a track record of raising venture funding to support development of related technologies and/or experience overseeing successful licensing of similar technologies to large industry partners. Ultimately, the skillsets of the proposed business executive hire should align with those needed to execute the proposed partnering plan.

While applying small businesses are not required to execute proposed hiring agreements prior to application submission, this FOA is designed to support applications that have identified at least one candidate within the application who provides the necessary expertise, along with a letter of support from the proposed candidate (see Section IV for application instructions).

The application also requires a letter of support from this candidate confirming interest and their support of the proposed hiring plan and activities described in the application. Please note that funding for this award may be restricted until a candidate that meets the required skillsets and expertise is officially hired.

Applicants are highly encouraged to utilize their network of advisors, board members, and consultants to identify strong candidates. Applicants should be actively seeking private funding or partnering at the time of application or within one year of application submission.

Readiness for fundraising and/or partnering activities should be demonstrated, such as through inclusion of letters of support from private funders, industry, and advisors; prior engagement with private partners; prior participation in company showcase opportunities or pitch competitions; and/or examples of comparable technologies and companies who succeeded in partnering at a similar development stage.

Activities proposed within applications to this funding opportunity must be directly related to private fundraising and partnering activities.

Partnering activities supported by this grant may include but are not limited to US-based travel to meet with potential partners, attendance at partnering meetings, legal activities related to partnering, and business development activities to address areas of interest of private partners (e.g. market and IP landscape analyses, regulatory plan development, business plan development, customer discovery research).

Partnering goals or milestones may include completing a number of meetings with investors, establishing a board of directors, finalizing pitch decks, and other business development activities that directly serve the proposed partnering goals.

This funding opportunity may support activities of other company staff, advisors, board members, consultants, lawyers, and/or vendors who will contribute to the proposed hiring and partnering activities.

Applicants are expected to meet with a minimum of ten potential partners over the duaration of the project fitting an appropriate target profile for the technology and company (e.g., angel investors, VC firms, pharma venture branches, industry search and evaluation staff, etc). Costs associated with conducting these meetings, including US-based travel and legal fees, are within scope.

Activities outside of product R&D that may directly contribute to successful partnering are within scope, such as market and intellectual property (IP) analyses, regulatory plan development, assembling a data room, and business plan development. The contribution of these activities to partnering success should be made clear by the applicant. Section I.

Funding Opportunity Description See Section VIII. Other Information for award authorities and regulations. Section II.

Award Information Grant: A support mechanism providing money, property, or both to an eligible entity to carry out an approved project or activity. Application Types Allowed New (for Phase II or IIB SBIR/STTR awards that will be active at the requested Project Start date). Renewal (for Phase II or IIB SBIR/STTR awards that have ended or will close out by the requested Project Start date).

New (for Phase II or IIB SBIR/STTR awards that will be active at the requested Project Start date) Renewal (for Phase II or IIB SBIR/STTR awards that have ended or will close out by the requested Project Start date) The OER Glossary and the SF424 (R&R) Application Guide provide details on these application types. Only those application types listed here are allowed for the FOA.

Not Allowed: Only accepting applications that do not propose clinical trials Need help determining whether you are doing a clinical trial? Funds Available and Anticipated Number of Awards The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. NIH is permitted to allocate not more than 10% of its overall SBIR funds allocated to the CRP program.

Total funding support (direct costs, indirect costs, fee) up to $400,000, with no more than $200,000 total cost per year, may be requested. Applicants are strongly encouraged to contact program officials prior to submitting any application and early in the application planning process . In all cases, applicants should propose a budget that is reasonable and appropriate for completion of the proposed project.

The scope of the proposed project should determine the project period. The maximum project period allowed is 2 years. NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this FOA.

Section III. Eligibility Information Only United States small business concerns (SBCs) that have had an active NIH SBIR or STTR Phase II or Phase IIB contract or grant award from NIH ICs within the last 36 months are eligible to submit applications for this opportunity. Only one CRP is allowed per Phase II or Phase IIB project.

SBCs with currently active and newly awarded Phase II or Phase IIB awards from one of the participating ICs are also eligible..

A small business concern is one that, at the time of award of Phase I and Phase II, meets all of the following criteria: Is organized for profit, with a place of business located in the United States, which operates primarily within the United States or which makes a significant contribution to the United States economy through payment of taxes or use of American products, materials or labor; Is in the legal form of an individual proprietorship, partnership, limited liability company, corporation, joint venture, association, trust or cooperative, except that where the form is a joint venture, there must be less than 50 percent participation by foreign business entities in the joint venture; SBIR and STTR.

Be a concern which is more than 50% directly owned and controlled by one or more individuals (who are citizens or permanent resident aliens of the United States), other business concerns (each of which is more than 50% directly owned and controlled by individuals who are citizens or permanent resident aliens of the United States), an Indian tribe, ANC or NHO (or a wholly owned business entity of such tribe, ANC or NHO), or any combination of these; OR SBIR-only.

Be a concern which is more than 50% owned by multiple venture capital operating companies, hedge funds, private equity firms, or any combination of these.

No single venture capital operating company, hedge fund, or private equity firm may own more than 50% of the concern, unless that single venture capital operating company, hedge fund , or private equity firm qualifies as a small business concern that is more than 50% directly owned and controlled by individuals who are citizens or permanent resident aliens of the United States; OR SBIR and STTR.

Be a joint venture in which each entity to the joint venture must meet the requirements set forth in paragraph 3 (i) or 3 (ii) of this section. A joint venture that includes one or more concerns that meet the requirements of paragraph (ii) of this section must comply with 121. 705(b) concerning registration and proposal requirements.

4. Has, including its affiliates, not more than 500 employees. If the concern is more than 50% owned by multiple venture capital operating companies, hedge funds, private equity firms, or any combination of these falls under 3 (ii) or 3 (iii) above, see Section IV.

Application and Submission Information for additional instructions regarding required application certification. If an Employee Stock Ownership Plan owns all or part of the concern, each stock trustee and plan member is considered an owner. If a trust owns all or part of the concern, each trustee and trust beneficiary is considered an owner.

Hedge fund has the meaning given that term in section 13(h)(2) of the Bank Holding Company Act of 1956 (12 U.S.C. 1851(h)(2)). The hedge fund must have a place of business located in the United States and be created or organized in the United States, or under the law of the United States or of any State.

Portfolio company means any company that is owned in whole or part by a venture capital operating company, hedge fund, or private equity firm. Private equity firm has the meaning given the term private equity fund in section 13(h)(2) of the Bank Holding Company Act of 1956 (12 U.S.C. 1851(h)(2)).

The private equity firm must have a place of business located in the United States and be created or organized in the United States, or under the law of the United States or of any State. Venture capital operating company means an entity described in 121. 103(b)(5)(i), (v), or (vi).

The venture capital operating company must have a place of business located in the United States and be created or organized in the United States, or under the law of the United States or of any State. ANC means Alaska Native Corporation. NHO means Native Hawaiian Organization.

SBCs must also meet the other regulatory requirements found in 13 C. F. R.

Part 121. Business concerns, other than investment companies licensed, or state development companies qualifying under the Small Business Investment Act of 1958, 15 U.S.C. 661, et seq.

, are affiliates of one another when either directly or indirectly, (a) one concern controls or has the power to control the other; or (b) a third-party/parties controls or has the power to control both. Business concerns include, but are not limited to, any individual (sole proprietorship) partnership, corporation, joint venture, association, or cooperative.

The SF424 (R&R) SBIR/STTR Application Guide should be referenced for detailed eligibility information. Small business concerns that are more than 50% owned by multiple venture capital operating companies, hedge funds, private equity firms, or any combination of these are NOT eligible to apply to the NIH STTR program.

Performance Benchmark Requirements Phase I to Phase II Transition Rate Benchmark: In accordance with guidance from the SBA, the HHS SBIR/STTR Program is implementing the Phase I to Phase II Transition Rate benchmark required by the SBIR/STTR Reauthorization Act of 2011 and the SBIR and STTR Extension Act of 2022.

The benchmark establishes a minimum number of Phase II awards the company must have received relative to a given number of Phase I awards received during the 5-fiscal year time period.

The Transition Rate is calculated as the total number of SBIR and STTR Phase II awards a company received during the past 5 fiscal years divided by the total number of SBIR and STTR Phase I awards it received during the past 5 fiscal years excluding the most recently-completed year.

The Transition Rate requirement, agreed upon and established by all 11 SBIR agencies, was published for public comment in a Federal Register Notice on October 16, 2012 (77 FR 63410) and amended on May 23, 2013 (78 FR 30951).

For SBIR and STTR Phase I applicants that have received more than 20 Phase I awards over the past 5 fiscal years (excluding the most recently-completed fiscal year): Companies that do not meet or exceed the benchmark minimum Transition Rate of 0. 25 will not be eligible to apply for a Phase I, Fast-Track, or Direct Phase II (if available) award for a period of one year from the date of the application submission.

This requirement does not apply to companies that have received 20 or fewer Phase I awards over the prior 5-fiscal year period. For application deadlines that fall on or after April 5, 2023: For SBIR and STTR Phase I applicants that have received more than 50 Phase I awards over the past 5 fiscal years (excluding the most recently-completed fiscal year): Companies that do not meet or exceed the benchmark minimum Transition Rate of 0.

5 will not be eligible to receive more than 20 total Phase I and Phase II awards for a period of one year from the date on which such determination is made. This requirement does not apply to companies that have received 50 or fewer Phase I awards over the 5-fiscal year period. On June 1 of each year, SBA will identify the companies that fail to meet minimum performance requirements.

SBA calculates individual company Phase I to Phase II Transition Rates using SBIR and STTR award information across all federal agencies. SBA will notify companies and the relevant officials at the participating agencies. More information on the Phase I to Phase II Transition Rate requirement is available at SBIR.

gov. Phase II to Commercialization Benchmark: In accordance with guidance from the SBA, the HHS SBIR/STTR Programs are implementing the Phase II to Commercialization Rate benchmark for Phase I applicants, as required by the SBIR/STTR Reauthorization Act of 2011 and the SBIR and STTR Extension Act of 2022.

The Commercialization Rate Benchmark was published in a Federal Register notice on August 8, 2013 ( 78 FR 48537 ), with a reopening of the comment period published on September 26, 2013 (78 FR 59410).

For companies that have received more than 15 Phase II awards from all agencies over the past 10 fiscal years (excluding the two most recently completed fiscal year): Companies that meet this criterion must show an average of at least $100,000 in revenues and/or investments per Phase II award or at least 0. 15 (15%) patents per Phase II award resulting from these awards during the past 10- fiscal year period.

Applicants that fail this benchmark will not be eligible to apply for New Phase I, Fast-track or Direct Phase II (if applicable) awards for a period of one year. This requirement does not apply to companies that have received 15 or fewer Phase II awards over the 10-fiscal year period, excluding the two most recently-completed fiscal years.

For application deadlines that fall on or after April 5, 2023: For companies that have received more than 50 Phase II awards from all agencies over the past 10-fiscal years (excluding the two most recently completed Fiscal Year): Companies that meet this criterion must show an average of at least $250,000 of aggregated sales and investment per Phase II award over the past 10-fiscal year period.

Applicants that fail this benchmark will not be eligible to receive more than 20 total Phase I and Phase II awards for a period of one year from the date on which such determination is made. This requirement does not apply to companies that have received 50 or fewer Phase II awards over the 10-fiscalyear period, excluding the two most recently-completed fiscal years.

For application deadlines that fall on or after April 5, 2023: For companies that have received more than 100 Phase II awards from all agencies over the past 10-fiscal years (excluding the two most recently completed Fiscal Year): Companies that meet this criterion must show an average of at least $450,000 of aggregated sales and investment per Phase II award over the past 10-fiscal year period.

Applicants that fail this benchmark will not be eligible to receive more than 20 total Phase I and Phase II awards for a period of one year from the date on which such determination is made. This requirement does not apply to companies that have received 100 or fewer Phase II awards over the 10-fiscalyear period, excluding the two most recently-completed fiscal years.

Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement , may be allowed.

Applicant organizations must complete and maintain the following registrations as described in the SF 424 (R&R) Application Guide to be eligible to apply for or receive an award. All registrations must be completed prior to the application being submitted. Registration can take 6 weeks or more, so applicants should begin the registration process as soon as possible.

The NIH Policy on Late Submission of Grant Applications states that failure to complete registrations in advance of a due date is not a valid reason for a late submission. System for Award Management (SAM) Applicants must complete and maintain an active registration, which requires renewal at least annually . The renewal process may require as much time as the initial registration.

SAM registration includes the assignment of a Commercial and Government Entity (CAGE) Code for domestic organizations which have not already been assigned a CAGE Code. Unique Entity Identifier (UEI)- A UEI is issued as part of the SAM. gov registration process.

The same UEI must be used for all registrations, as well as on the grant application. SBA Company Registry See Section IV. Application and Submission Information , SF424(R&R) Other Project Information Component for instructions on how to register and how to attach proof of registration to your application package.

Applicants must have a UEI to complete this registration. SBA Company registration is NOT required before SAM, Grants. gov or eRA Commons registration.

eRA Commons - Once the unique organization identifier is established, organizations can register with eRA Commons in tandem with completing their Grants. gov registration; all registrations must be in place by time of submission. eRA Commons requires organizations to identify at least one Signing Official (SO) and at least one Program Director/Principal Investigator (PD/PI) account in order to submit an application.

Grants. gov Applicants must have an active SAM registration in order to complete the Grants. gov registration.

Program Directors/Principal Investigators (PD(s)/PI(s)) All PD(s)/PI(s) must have an eRA Commons account. PD(s)/PI(s) should work with their organizational officials to either create a new account or to affiliate their existing account with the applicant organization in eRA Commons. If the PD/PI is also the organizational Signing Official, they must have two distinct eRA Commons accounts, one for each role.

Obtaining an eRA Commons account can take up to 2 weeks. Eligible Individuals (Program Director/Principal Investigator) Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support.

For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the SF424 (R&R) Application Guide. Under the SBIR program, for both Phase I and Phase II, the primary employment of the PD/PI must be with the small business concern at the time of award and during the conduct of the proposed project.

For projects with multiple PDs/PIs, at least one must meet the primary employment requirement. Occasionally, deviations from this requirement may occur.

For the STTR program, the PD(s)/PI(s) may be employed with the SBC or the single, partnering non-profit research institution as long as s/he has a formal appointment with or commitment to the applicant SBC, which is characterized by an official relationship between the SBC and that individual.

Such a relationship does not necessarily involve a salary or other form of remuneration The primary employment of the PD/PI must be with the SBC or the Research Institution (where they are PD/PI at) at the time of award and during the conduct of the proposed project. Each PD/PI must commit a minimum of 10% effort to the project.

The SF424 (R&R) SBIR/STTR Application Guide should be referenced for specific details on eligibility requirements. For institutions/organizations proposing multiple PDs/PIs, see Multiple Principal Investigators section of the SF424 (R&R) SBIR/STTR Application Guide. This FOA